Tseng, Ping-TaoPing-TaoTsengZeng, Bing-YanBing-YanZengChen, Yen-WenYen-WenChenYang, Chun-PaiChun-PaiYangSu, Kuan-PinKuan-PinSuChen, Tien-YuTien-YuChenWu, Yi-ChengYi-ChengWuYU-KANG TULin, Pao-YenPao-YenLinCarvalho, Andre FAndre FCarvalhoStubbs, BrendonBrendonStubbsMatsuoka, Yutaka JYutaka JMatsuokaLi, Dian-JengDian-JengLiLiang, Chih-SungChih-SungLiangHsu, Chih-WeiChih-WeiHsuSun, Cheuk-KwanCheuk-KwanSunCheng, Yu-ShianYu-ShianChengYeh, Pin-YangPin-YangYehShiue, Yow-LingYow-LingShiue2023-03-252023-03-2520221570-159Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85137316088&doi=10.2174%2f1570159X20666220420122322&partnerID=40&md5=995e1e92e22ee38a388de09cf0c7e770https://scholars.lib.ntu.edu.tw/handle/123456789/629675While Alzheimer's dementia (AD) has a prevalence as high as 3-32% and is associated with cognitive dysfunction and the risk of institutionalization, no efficacious and acceptable treatments can modify the course of cognitive decline in AD. Potential benefits of exogenous melatonin for cognition have been divergent across trials.enAlzheimer’s dementia; circadian rhythm; cognition; dementia; melatonin; network meta-analysis; psychiatry; quality of life[SDGs]SDG3The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials10.2174/1570159X20666220420122322354505252-s2.0-85137316088WOS:000858546800005https://api.elsevier.com/content/abstract/scopus_id/85137316088